Insider · SEC Form 4 filer

Srinivas Akkaraju

Past buys: 3 of 7 beat

Companies

Where they file as an insider

Scholar Rock Holding (SRRK) Director Latest filing Oct 26, 2026
Alumis (ALMS) Director Latest filing Sep 8, 2026
Mineralys Therapeutics (MLYS) Director, 10% owner Latest filing Feb 19, 2026
Kalaris Therapeutics (KLRS) Director, 10% owner Latest filing Dec 22, 2025
vTv Therapeutics (VTVT) Director Latest filing Sep 22, 2025
Neurogene (NGNE) 10% owner Latest filing Nov 26, 2024
Syros Pharmaceuticals (SYRS) Director Latest filing Sep 16, 2024
Cargo Therapeutics (CRGX) 10% owner Latest filing Nov 14, 2023

And 1 more company with older filings.

Track record

Did their buys beat the typical stock?

Open-market buys41
Quarters checked 6 months later7
Beat the typical stock 3 of 7
Quarters too new to check2

3 of 7 checked quarters beat the typical stock. A past record is data, not a forecast.

Scholar Rock Holding (SRRK) Bought Oct 23–26, 2026 · $12M · 289,470 shares Too new Too new. Its 6-month check uses prices as of Jun 30, 2027.
Alumis (ALMS) Bought Sep 4–8, 2026 · $10.7M · 986,721 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Alumis (ALMS) Bought Jan 9, 2026 · $10M · 588,235 shares Behind typical Mar 31, 2026 $22.03 → Sep 30, 2026 $7.39 · −66.5% (typical stock +1.7%)
Alumis (ALMS) Bought Nov 13–Dec 5, 2025 · $9.07M · 1.27M shares Beat typical Dec 31, 2025 $9.76 → Jun 30, 2026 $28.14 · +188.3% (typical stock +4.7%)
Scholar Rock Holding (SRRK) Bought Oct 3–7, 2025 · $20M · 530,038 shares Beat typical Dec 31, 2025 $44.05 → Jun 30, 2026 $55.00 · +24.9% (typical stock +4.7%)
Mineralys Therapeutics (MLYS) Bought Sep 4, 2025 · $15M · 588,235 shares Behind typical Sep 30, 2025 $37.92 → Mar 31, 2026 $27.09 · −28.6% (typical stock −3.4%)
Alumis (ALMS) Bought May 2–5, 2025 · $1.48M · 320,290 shares Not counted Not counted. We have no fund price for this stock on both Jun 30, 2025 and Dec 31, 2025.
Mineralys Therapeutics (MLYS) Bought Mar 13, 2025 · $8.1M · 600,000 shares Beat typical Mar 31, 2025 $15.88 → Sep 30, 2025 $37.92 · +138.8% (typical stock +7.3%)
Syros Pharmaceuticals (SYRS) Bought Dec 21, 2023 · $4M · 904,977 shares Behind typical Dec 31, 2023 $7.79 → Jun 30, 2024 $5.16 · −33.8% (typical stock −1.2%)
Scholar Rock Holding (SRRK) Bought Oct 16, 2023 · $15M · 2.19M shares Behind typical Dec 31, 2023 $18.80 → Jun 30, 2024 $8.33 · −55.7% (typical stock −1.2%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist